Lindsay Androski
Board Member
Arbutus Biopharma Corp (ABUS)Chairman
Arbutus Biopharma Corp (ABUS)Board Member
Eloxx Pharmaceuticals, Inc. (ELOX)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Lindsay Androski
Lindsay Androski is recorded as CEO, Board Member and Chairman at Arbutus Biopharma Corp (ABUS) and Board Member at Eloxx Pharmaceuticals, Inc. (ELOX). Eloxx Pharmaceuticals, Inc. reported in an 8-K filed August 12, 2025 that Lindsay Androski resigned as Board, effective August 6, 2025. Arbutus Biopharma Corp reported in an 8-K filed February 25, 2025 that Lindsay Androski was appointed chairperson of the Board, effective February 24, 2025. Arbutus Biopharma Corp reported in an 8-K filed February 25, 2025 that Lindsay Androski was appointed President and Chief Executive Officer, effective February 24, 2025. Equibles holds 5 filed executive changes naming Lindsay Androski; each is listed under recent activity with its source filing. The proxy statement of Arbutus Biopharma Corp reports total compensation of $1,369,013 for Lindsay Androski in fiscal 2025, including a base salary of $437,750. Disclosed compensation is on record for 2 fiscal years.
“On August 6, 2025, Ms. Lindsay Androski notified the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) of her resignation from the Board.”
“Following such appointments, the Board appointed Ms. Androski as chairperson of the Board”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2025-02-24–present
-
Current
2025-02-24–present
-
Current
2022-07-01–present
-
Current
Start not stated–present
-
Start not stated–2025-08-06
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Arbutus Biopharma Corp
Other people whose current roles at this company are on record from its filings.
- Mark J. Murray CEO
- Michael J. McElhaugh CEO, COO, Board Member
- Tuan Nguyen CFO
- Michael McElhaugh COO
- Mike McElhaugh COO
- J. Christopher Naftzger General Counsel
- Anuj Hasija Board Member
- Eric Venker, M.D., Pharm.D. Board Member
- Frank Torti, M.D. Board Member
- Joseph Bishop Board Member
Leadership on record at Eloxx Pharmaceuticals, Inc.
Other people whose current roles at this company are on record from its filings.
- Sumit Aggarwal CEO, Board Member
- Daniel Geffken CFO, Chief Accounting Officer
- Gary D. Rakers CFO
- Neil S. Belloff COO
- Alan Walts Board Member
- Alan Walts, Ph.D. Board Member
- Nina Kjellson Board Member
- Raj Parekh Board Member
- Raj Parekh, Ph.D. Board Member
- Stephen W. Webster Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Arbutus Biopharma Corp (ABUS) | President and Chief Executive Officer | $437,750 | $1,369,013 |
| 2024 | Arbutus Biopharma Corp (ABUS) | President and Chief Executive Officer | — | — |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.